Circulating Tumor Cells as Diagnostic and Therapeutic Biomarkers in Hepatocellular Carcinoma: Advancing Precision Oncology Through Liquid Biopsy
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70197 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Mutaz Jamal Al-Khreisat und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Carcinoma, Hepatocellular, Liver Neoplasms, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 153 Literaturangaben.
Abstract (Originalsprache)
Circulating tumor cells (CTCs) are emerging as promising biomarkers in hepatocellular carcinoma (HCC), offering noninvasive insight into tumor biology, progression, and treatment response. Advances in enrichment and single‐cell technologies have enabled the characterization of CTCs at genomic, transcriptomic, epigenetic, and proteomic levels. CTC detection correlates with tumor stage, vascular invasion, and alpha‐fetoprotein levels, supporting their role in early diagnosis and staging. Specific surface markers such as epithelial cell adhesion molecule, GPC3, ASGPR, and stem cell–associated antigens like CD90 and CD133 help classify CTC subtypes with prognostic and therapeutic relevance. Mesenchymal and hybrid phenotypes, identified via epithelial‐to‐mesenchymal transition markers, are linked to recurrence and metastasis. Furthermore, CTCs provide a platform for companion diagnostics by reflecting mutational and resistance profiles, particularly in the context of targeted therapies and immune checkpoint inhibitors. Despite current limitations in standardization, sensitivity, and scalability, the integration of CTC analysis into clinical practice holds potential to enhance precision medicine strategies in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
- College of Pharmacy, The Islamic University, Najaf, Iraq.
- College of Pharmacy, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.
- Faculty of Pharmacy, Gokul Global University, Sidhpur, Gujarat, India.
- Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, Odisha, India.
Zitieren
APA
Al-Khreisat, M. J., Kadhim-Abosaoda, M., Abas Ibrahim, N., Malathi H, M., Priyadarshini-Nayak, P., Sathiya-Priya, V., Singh, G., & Chauhan, A. S. (2026). Circulating Tumor Cells as Diagnostic and Therapeutic Biomarkers in Hepatocellular Carcinoma: Advancing Precision Oncology Through Liquid Biopsy. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70197
Vancouver
Al-Khreisat MJ, Kadhim-Abosaoda M, Abas Ibrahim N, Malathi H M, Priyadarshini-Nayak P, Sathiya-Priya V, et al. Circulating Tumor Cells as Diagnostic and Therapeutic Biomarkers in Hepatocellular Carcinoma: Advancing Precision Oncology Through Liquid Biopsy. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70197
BibTeX
@article{AlKhreisat2026,
author = {Al-Khreisat, Mutaz Jamal and Kadhim-Abosaoda, Munthar and Abas Ibrahim, Namim and Malathi H, Ms and Priyadarshini-Nayak, Priya and Sathiya-Priya, V and Singh, Gurjant and Chauhan, Ashish Singh},
title = {Circulating Tumor Cells as Diagnostic and Therapeutic Biomarkers in Hepatocellular Carcinoma: Advancing Precision Oncology Through Liquid Biopsy},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70197}
}
EUVIMED